Effect of Atazanavir on Endothelial Function in HIV-Infected Patients
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
It is known that certain antiviral therapies, the socalled protease inhibitors, used in the
treatment of HIV infection has an untowarded effect on the blood vessels, promoting early
occurence of atherosclerosis. A a newer protease inhibitor, atazanavir, has been shown to
have no negative effect on the levels of blood cholesterol and it is hypothesized that this
may indicate that atazanavir is less prone to induce atherosclerosis. An early sign of
atherosclerosis is a reduced vasomotion and this study investigate the influence of
atazanavir on functionality of the conduit blood vessels compared to that of "standard"
antiviral therapy.